There are chapters in life that arrive quietly, marked not by dramatic flair but by hushed determination—moments when a routine test, a conversation with a clinician, and a leap into something new conspire to reshape an ordinary story into one of renewal. For James Choate‑Deeds, a father and architect who faced an unexpected prostate cancer diagnosis in his late 50s, that chapter came not with dread but with a curious partnership: a surgeon, a family by his side, and a robot named Hugo that would help him write a new page in his life.
Choate-Deeds’s journey began with vigilance—a proactive decision to undergo a prostate-specific antigen (PSA) test even when his doctor believed it wasn’t strictly necessary. When his PSA levels eventually trended upward, further biopsies confirmed prostate cancer in June 2022. Rather than retreat, he explored options, seeking not just survival but a path that might preserve the rhythms of his active life.
That exploration led him to join a clinical trial for the Hugo robotic-assisted surgery system, developed by Medtronic and designed to provide precise, minimally invasive surgical assistance. Under the care of urologist James Porter, Choate-Deeds underwent surgery on December 22, 2022. From a console positioned several feet from his body, the surgeon guided Hugo’s robotic arms through tiny incisions with meticulous control, enabling the complete removal of cancerous tissue.
Recovery, in turn, unfolded with surprising ease. Within 24 hours, Choate-Deeds was walking, leaving behind only small scars no larger than an ink-pen tip. He needed no follow-up chemotherapy or radiation, and within months he was back on the ice playing hockey and planning ski trips with his family—activities that had once defined his everyday life. “There’s nothing I don’t do that I did before,” he reflected, crediting early detection, supportive family, and the innovative technology that carried him through the operation.
The Hugo system itself represents a newer generation of surgical robotics. Recently approved by the U.S. Food and Drug Administration for urologic procedures, including prostate, kidney, and bladder cancer interventions, Hugo is part of a broader shift toward minimally invasive surgery that seeks to reduce recovery times and physical trauma compared with traditional approaches.
Choate-Deeds’s experience speaks to this promise: a surgical encounter where precision blended with humanity, and where the familiar contours of family life resumed more swiftly than many had expected. In urging others to be proactive about PSA screening and to explore robotic-assisted surgery when eligible, he hopes his story might be both lesson and encouragement to those at similar crossroads.
For now, Choate-Deeds continues to live fully, a testament to what early detection and evolving medical technology can achieve together. As the landscape of cancer care continues to change, advances like the Hugo system offer new possibilities—not only for survival, but for the quality of life that follows.
AI Image Disclaimer: Graphics are AI-generated and intended for representation, not reality.
Sources: People (via People.com / Yahoo News Singapore) Medtronic robotic surgery coverage